EFFICACY AND SAFETY PROFILE OF DASATINIB IN A SUBSET OF VERY ELDERLY PATIENS WITH CHRONIC MYELOID LEUKEMIA (CML) RESISTANT/INTOLERANT TO IMATINIB
Francesco Cavazzini(Arcispedale Sant'Anna), G Gozzini, Raffaele Porrini, Dario Ferrero(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Mario Tiribelli(University of Udine), G Rosti, Elena Saccenti(University of Ferrara), Patrizia Pregno(Azienda Ospedaliero Universitaria San Giovanni Battista), Luigia Luciano, Costanzo Feo, Elisabetta Abruzzese(St. Eugenio Hospital), Ubaldo Occhini, Simona Sica(San Antonio College), Fabio Stagno, Gianni Binotto(University of Padua), Massimo Breccia(Policlinico Umberto I), Carmen Fava, P. Musto(University of Indianapolis), Santini, Enrico Montefusco(Thrombolysis in Myocardial Infarction Study Group), Roberto Latagliata(Ospedale di Belcolle), B. Martino(Azienda ospedaliera "Bianchi-Melacrino-Morelli"), Giuliana Alimena
Institutional Research Information System University of Ferrara (University of Ferrara)
January 1, 2010
Cited by 1
Related Papers
Retinoic Acid and Arsenic Trioxide for Acute Promyelocytic Leukemia
|New England Journal of Medicine|2013|1.6k
Quizartinib versus salvage chemotherapy in relapsed or refractory FLT3-ITD acute myeloid leukaemia (QuANTUM-R): a multicentre, randomised, controlled, open-label, phase 3 trial
|The Lancet Oncology|2019|486
Asciminib in Chronic Myeloid Leukemia after ABL Kinase Inhibitor Failure
|New England Journal of Medicine|2019|464